Tandem Diabetes Care (TNDM) Reports Q3 Earnings: What Key Metrics Have to Say

Zacks11-07

For the quarter ended September 2024, Tandem Diabetes Care, Inc. (TNDM) reported revenue of $243.97 million, up 31.4% over the same period last year. EPS came in at -$0.36, compared to -$0.38 in the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481946999?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/kz0ozt3ejWMPXKci2JxOBw--~B/aD03NTQ7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/d7dcbe11345e3f8e5e71e6827fe3c4c9","is_english":true,"pubTime":"2024-11-07 07:30","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2481946999","market":"us","top_or_hot":-1,"title":"Tandem Diabetes Care (TNDM) Reports Q3 Earnings: What Key Metrics Have to Say","media":"Zacks","content":"<div>\n<p>For the quarter ended September 2024, Tandem Diabetes Care, Inc. (TNDM) reported revenue of $243.97 million, up 31.4% over the same period last year. EPS came in at -$0.36, compared to -$0.38 in the ...</p>\n\n<a href=\"https://finance.yahoo.com/news/tandem-diabetes-care-tndm-reports-233015104.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tandem Diabetes Care (TNDM) Reports Q3 Earnings: What Key Metrics Have to Say</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTandem Diabetes Care (TNDM) Reports Q3 Earnings: What Key Metrics Have to Say\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-07 07:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/tandem-diabetes-care-tndm-reports-233015104.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>For the quarter ended September 2024, Tandem Diabetes Care, Inc. (TNDM) reported revenue of $243.97 million, up 31.4% over the same period last year. EPS came in at -$0.36, compared to -$0.38 in the ...</p>\n\n<a href=\"https://finance.yahoo.com/news/tandem-diabetes-care-tndm-reports-233015104.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TNDM","symbol_name":"糖尿病保健","start_time":0,"source_url":"https://finance.yahoo.com/news/tandem-diabetes-care-tndm-reports-233015104.html","article_id":"2481946999","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/kz0ozt3ejWMPXKci2JxOBw--~B/aD03NTQ7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/d7dcbe11345e3f8e5e71e6827fe3c4c9"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481946999","pubTimestamp":1730935815,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"For the quarter ended September 2024, Tandem Diabetes Care, Inc.  reported revenue of $243.97 million, up 31.4% over the same period last year. EPS came in at -$0.36, compared to -$0.38 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $223.33 million, representing a surprise of +9.24%. The company delivered an EPS surprise of +16.28%, with the consensus EPS estimate being -$0.43.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.Pump Shipments - Total Worldwide: 32,000 versus the two-analyst average estimate of 29,722.Pump Shipments - United States: 21,000 compared to the 20,985 average estimate based on two analysts.Sales- Pump- Outside the United States: $28.08 million versus $22.34 million estimated by three analysts o","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"TNDM":"糖尿病保健"},"translate_title":"Tandem Diabetes Care(TNDM)报告第三季度收益：关键指标说明了什么","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TNDM":1},"content_text":"For the quarter ended September 2024, Tandem Diabetes Care, Inc. (TNDM) reported revenue of $243.97 million, up 31.4% over the same period last year. EPS came in at -$0.36, compared to -$0.38 in the year-ago quarter.\nThe reported revenue compares to the Zacks Consensus Estimate of $223.33 million, representing a surprise of +9.24%. The company delivered an EPS surprise of +16.28%, with the consensus EPS estimate being -$0.43.\nWhile investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.\nAs these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.\nHere is how Tandem Diabetes Care performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: \n\nPump Shipments - Total Worldwide: 32,000 versus the two-analyst average estimate of 29,722.\nPump Shipments - Outside the United States: 11,000 versus 8,738 estimated by two analysts on average.\nPump Shipments - United States: 21,000 compared to the 20,985 average estimate based on two analysts.\nSales- Pump- United States: $86.72 million compared to the $84.60 million average estimate based on four analysts. The reported number represents a change of +30.7% year over year.\nSales- Supplies and Other- United States: $83.89 million versus $78.68 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +16.4% change.\nGeographic Sales- Outside the United States: $72.32 million compared to the $59.84 million average estimate based on four analysts. The reported number represents a change of +30.5% year over year.\nGeographic Sales- United States: $171.65 million compared to the $163.28 million average estimate based on four analysts. The reported number represents a change of +31.8% year over year.\nSales- Supplies and Other- Outside the United States: $44.24 million versus $37.44 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +31.2% change.\nSales- Pump- Outside the United States: $28.08 million versus $22.34 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +29.6% change.\nRevenue- Supplies and Other: $128.13 million compared to the $115.91 million average estimate based on four analysts.\nRevenue- Pump: $114.80 million compared to the $107.07 million average estimate based on four analysts.\n View all Key Company Metrics for Tandem Diabetes Care here>>>\n\nShares of Tandem Diabetes Care have returned -17% over the past month versus the Zacks S&P 500 composite's +0.7% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.\n\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nTandem Diabetes Care, Inc. (TNDM) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481946999"}